Overview
My area of clinical research is drug development focused on novel antithrombotic medications, with the express purpose of obtaining worldwide regulatory approval. My goal is to bring new pharmaceutical treatments for patients with venous and arterial thromboembolic disease to healthcare providers.
Key Words
anticoagulants antiplatelet medications antithrombotic drugs arterial thrombosis bleeding diatheses hemostasis hypercoagulable states prophylaxis thrombocytopenia thrombosis thromboembolic disease treatment venous thrombosis
von Willebrand disease
Key Words
anticoagulants antiplatelet medications antithrombotic drugs arterial thrombosis bleeding diatheses hemostasis hypercoagulable states prophylaxis thrombocytopenia thrombosis thromboembolic disease treatment venous thrombosis
von Willebrand disease
Current Appointments & Affiliations
Adjunct Associate Professor in the Department of Medicine
·
2000 - Present
Medicine, Hematology,
Medicine
Recent Publications
Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
Journal Article Ann Intern Med · October 15, 2002 Featured Publication BACKGROUND: Warfarin is used for prophylaxis of venous thromboembolism in patients undergoing total knee arthroplasty. However, it is associated with rates of deep venous thrombosis (DVT) of approximately 38% to 55% and requires routine coagulation monitor ... Full text Link to item CiteHeparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries.
Journal Article Am Heart J · July 2002 Featured Publication BACKGROUND: This study analyzed relationships among heparin dosage, patient characteristics, and 30-day outcome because optimal unfractionated-heparin dosing in acute coronary syndromes remains uncertain. METHODS: Patients (n = 5335) randomized to heparin ... Full text Link to item CiteDetermination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.
Journal Article Am Heart J · July 2002 BACKGROUND: A simple device to rapidly evaluate platelet function may aid in optimizing glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention (PCI). We prospectively studied platelet function in 250 patients receiving abciximab or epti ... Full text Link to item CiteEducation, Training & Certifications
Thomas Jefferson University ·
1979
M.D.